PRESIDENT TRUMP HOSPITALIZED FOR COVID 19
RYAN CASSIN is CEO OF Beast Digital, a Dallas-based digital strategy and communications firm.
Cassin is a digital and PR strategist at the intersection of business, politics and technology. Cassin has led digital programs for corporations, non-profits, hedge funds, universities, and political campaigns ranging from legislative caucuses to multimillion-dollar statewide races. Before discovering politics, Cassin began his career at age 14 as a sought-after software developer and is one of the youngest credited developers of the Firefox web browser.
THE ONGOING ECONOMIC IMPACT
Recognized Expert on Personal Finance, the Economy, and the Markets; And Syndicated Columnist TERRY SAVAGE is our guest.
Savage is a nationally recognized expert on personal finance, the economy, and the markets. She writes a weekly personal finance column syndicated in major newspapers by Tribune Content Agency. She is the author of four best-selling books on personal finance. A new edition of her best-selling book, The Savage Truth on Money is now available on Amazon.com. The first edition was named one of the top ten money books of the year by Amazon.com. Her other recent book is: The Savage Number: How Much Money do You Really Need to Retire? She is also co-author of The New Love Deal. You can read Terry’s weekly columns and commentaries, watch videos, check out links to her favorite websites and calculators, and check out Q&A on her “Ask Terry” blog at www.TerrySavage.com.
THE MEDICAL ASPECTS OF THE PRESIDENT’S COVID-19 DIAGNOSIS
DEAN L. FANELLI, Ph.D., is Partner At Seyfarth Shaw LLp in the Washington D.C. Metro Area.
Fanelli’s expertise lies in patent portfolio creation and management, counseling, technology transactions, due diligence, opinion work, including drafting novelty, freedom-to-operate, and invalidity opinions, and inter partes review and post grant review proceedings. Dr. Fanelli also has significant experience with the interplay between patent and FDA laws under the Hatch-Waxman Act, and he regularly handles IP issues attendant to mergers, acquisitions, and financing for life sciences companies as well as ANDA analyses associated with Hatch-Waxman paragraph IV litigation.